Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 2/20 | 0.62 |
| ▸ | ESR1 | P03372 | 5/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578831 | 0.87 | ESR1 (0.52) | NR1H3ESR1ESR2POLBMEN1 | |
| SCHEMBL887456 | 0.86 | NR1H3 (0.79) | NR1H3ESR1ESR2APAF1POLB | |
| SCHEMBL14514790 | 0.83 | ESR1 (0.49) | NR1H3ESR1ESR2MEN1KMT2A | |
| SCHEMBL7912444 | 0.83 | ESR1 (0.59) | NR1H3ESR1ESR2APAF1POLB | |
| SCHEMBL13871737 | 0.81 | KMT2A (0.58) | NR1H3CA9MEN1KMT2ASCN2A | |
| SCHEMBL11565884 | 0.78 | KMT2A (0.55) | NR1H3CA9MEN1KMT2ASCN2A | |
| SCHEMBL22862089 | 0.78 | MGLL (0.71) | ESR1ESR2MEN1KMT2A | |
| SCHEMBL28029844 | 0.78 | MGLL (0.71) | ESR1ESR2MEN1KMT2A | |
| SCHEMBL15858818 | 0.77 | NR1H3 (0.81) | NR1H3ESR1ESR2APAF1POLB | |
| SCHEMBL14494705 | 0.77 | NR1H3 (0.66) | NR1H3ESR1ESR2APAF1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963399-B1 | POLYCYCLIC DIHYDROXY COMPOUNDS AND METHODS FOR PREPARATION | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2016-07-27 | — | — | EP | disclosed |
| US-7425603-B2 | Polymers, polymer compositions, and method of preparation | GENERAL ELECTRIC COMPANY (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425603-B2 | Polymers, polymer compositions, and method of preparation | GENERAL ELECTRIC COMPANY (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425603-B2 | Polymers, polymer compositions, and method of preparation | GENERAL ELECTRIC COMPANY (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1963399-A2 | CHROMANE SUBSTITUTED 2-ALKYL IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS ACID PUMP ANTAGONIST | General Electric Company (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007064569-A2 | CHROMANE SUBSTITUTED 2 -ALKYL IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS ACID PUMP ANTAGONISTS | GENERAL ELECTRIC COMPANY (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064569-A2 | CHROMANE SUBSTITUTED 2 -ALKYL IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS ACID PUMP ANTAGONISTS | GENERAL ELECTRIC COMPANY (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20070123713-A1 | Polycyclic dihydroxy compound and methods for preparation | CITIBANK, N.A., AS COLLATERAL AGENT | 2007-05-31 | — | — | US | disclosed |
| US-20070123713-A1 | Polycyclic dihydroxy compound and methods for preparation | CITIBANK, N.A., AS COLLATERAL AGENT | 2007-05-31 | — | — | US | disclosed |
| US-20070123713-A1 | Polycyclic dihydroxy compound and methods for preparation | CITIBANK, N.A., AS COLLATERAL AGENT | 2007-05-31 | — | — | US | disclosed |
| US-20070123682-A1 | Polycarbonates, polyesters, polycarbonateesters, polyurethanes and epoxy resins prepared from monomers including N-4-[1,1'-di(p-hydroxyphenyl)ethyl]phenyl phthalimide or derivatives; articles with improved chemical resistance and high glass transition temperatures and refractive indices | SABIC GLOBAL TECHNOLOGIES IP B.V. (NL) | 2007-05-31 | — | — | US | disclosed |
| US-20070123682-A1 | Polycarbonates, polyesters, polycarbonateesters, polyurethanes and epoxy resins prepared from monomers including N-4-[1,1'-di(p-hydroxyphenyl)ethyl]phenyl phthalimide or derivatives; articles with improved chemical resistance and high glass transition temperatures and refractive indices | SABIC GLOBAL TECHNOLOGIES IP B.V. (NL) | 2007-05-31 | — | — | US | disclosed |
| US-20070123682-A1 | Polycarbonates, polyesters, polycarbonateesters, polyurethanes and epoxy resins prepared from monomers including N-4-[1,1'-di(p-hydroxyphenyl)ethyl]phenyl phthalimide or derivatives; articles with improved chemical resistance and high glass transition temperatures and refractive indices | SABIC GLOBAL TECHNOLOGIES IP B.V. (NL) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123713-A1 | Polycyclic dihydroxy compound and methods for preparation | PAH, DDT, CYP24A1 | NR1H3 330/4885ESR1 554/4885ESR2 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.